| dbo:abstract
|
- Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China. (en)
- 赛沃替尼（Savolitinib）商品名沃瑞沙（Orpathys），是一种实验性的小分子抑制剂。阿斯利康制药正在研究赛沃替尼以用于治疗癌症，同時赛沃替尼治療腺癌、和的 II 期临床试验也已展開。 2021年6月，国家药品监督管理局允許和记黄埔医药（上海）有限公司申报的赛沃替尼片上市。 (zh)
|
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 3520 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:h
| |
| dbp:iupacName
| |
| dbp:kegg
| |
| dbp:n
| |
| dbp:smiles
|
- C[C@@H]n1nnc2nccnc21 (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- XYDNMOZJKOGZLS-NSHDSACASA-N (en)
|
| dbp:synonyms
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China. (en)
- 赛沃替尼（Savolitinib）商品名沃瑞沙（Orpathys），是一种实验性的小分子抑制剂。阿斯利康制药正在研究赛沃替尼以用于治疗癌症，同時赛沃替尼治療腺癌、和的 II 期临床试验也已展開。 2021年6月，国家药品监督管理局允許和记黄埔医药（上海）有限公司申报的赛沃替尼片上市。 (zh)
|
| rdfs:label
|
- Savolitinib (en)
- 赛沃替尼 (zh)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
